Neuraminidase inhibitors: widespread use for influenza may reveal more adverse effects

摘要

The neuraminidase inhibitors (NAIs), oseltamivir (Tamiflu) and zanamivir (Relenza), are indicated for prophylaxis and treatment of influenza. Both antivirals are included within the current UK Health Protection Agency guidance for the treatment and prophylaxis of infection from the novel swine influenza A (H1N1) virus. These drugs are more effective and safer than older antivirals, such as the amantanes (amantidine and rimantadine). In the event of a global pandemic the NAIs will be administered to a large proportion of the population.